Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, marketing, and sale of pharmaceuticals worldwide. The company offers pharmaceuticals in various therapeutic areas, including cardiovascular, dermatology, over the counter/non-prescription pharmaceuticals, urology, anti-infectives, central nervous system, gastrointestinal, gynecology and obstetrics, musculo-skeletal disorders and analgesia, nutrition and related products, cosmetics, dietary supplements, medical devices, allergy, endocrinology, respiratory, pain management/inflammation, generics, antipyretics and cold preparations, and oncology, as well as ear, nose, and throat. It also provides products for rare diseases; and pharmaceutical chemicals, such as chemical syntheses, active pharmaceutical ingredients, and intermediates. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. operates as a subsidiary of Rossini S.à R.L.
Revenue of Recordati Industria Chimica e Farmaceutica S.p.A. (REC.MI)
Revenue in 2023 (TTM): $2.25 B
According to Recordati Industria Chimica e Farmaceutica S.p.A.'s latest financial reports the company's current revenue (TTM) is $2.25 B. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Recordati Industria Chimica e Farmaceutica S.p.A.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $2.25 B | $1.54 B | $766.52 M | $531.3 M | $421.13 M |
| 2022 | $2.01 B | $1.39 B | $669.88 M | $434.35 M | $337.95 M |
| 2021 | $1.71 B | $1.25 B | $645.21 M | $501.34 M | $417.61 M |
| 2020 | $1.57 B | $1.13 B | $620.46 M | $493.02 M | $384.09 M |
| 2019 | $1.6 B | $1.13 B | $589 M | $480.56 M | $399.07 M |
| 2018 | $1.46 B | $1.04 B | $540.75 M | $452.2 M | $337.99 M |
| 2017 | $1.39 B | $979.6 M | $488.6 M | $421.02 M | $312.44 M |
| 2016 | $1.25 B | $858 M | $410.72 M | $343.3 M | $256.87 M |
| 2015 | $1.13 B | $770.88 M | $346.09 M | $287.2 M | $215.09 M |
| 2014 | $1.07 B | $714.44 M | $300.91 M | $232.39 M | $174.4 M |
| 2013 | $1.02 B | $664.67 M | $259.19 M | $195.62 M | $144.64 M |
| 2012 | $896.23 M | $578.61 M | $223.01 M | $173.48 M | $128.2 M |
| 2011 | $824.52 M | $543.22 M | $203.14 M | $173.13 M | $125.99 M |
| 2010 | $787.84 M | $528.09 M | $196.64 M | $163.38 M | $117.48 M |
| 2009 | $808.82 M | $553.87 M | $209.11 M | $165.17 M | $119.63 M |
| 2008 | $746.18 M | $505.77 M | $188.45 M | $149.47 M | $108.66 M |
| 2007 | $679.96 M | $456.69 M | $170.38 M | $137.87 M | $91.82 M |
| 2006 | $623.43 M | $415.67 M | $155.43 M | $127.87 M | $80.1 M |
| 2005 | $623.31 M | $406.24 M | $144.11 M | $115.77 M | $69.84 M |
| 2004 | $528.35 M | $334.37 M | $121.91 M | $93.83 M | $58.39 M |
| 2003 | $527.51 M | $311.38 M | $77.5 M | $41.59 M | $25.69 M |